SUDO-550 / Sudo Biosci - LARVOL DELTA

Sudo Biosciences Announces First Participants Dosed in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550 (Businesswire) - "Sudo Biosciences...announced today that the first participants have been dosed in a Phase 1 clinical trial evaluating SUDO-550, a novel brain-penetrant allosteric TYK2 inhibitor for the treatment of neuroinflammatory diseases. The Phase 1 clinical trial is designed to evaluate the safety, tolerability, and pharmacokinetics of single and multiple-ascending doses of SUDO-550 in healthy volunteers, including confirmation that the compound effectively crosses the blood-brain barrier."

Trial status • Immunology • Inflammation

Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M (Businesswire) - "Sudo Biosciences...today announced that during January 2024, it completed a second close of its Series B financing, raising an additional $30 million from new investors Dementia Discovery Fund (DDF, a SV Health Investors Fund), Leaps by Bayer, and UPMC Enterprises, the innovation, commercialization and venture capital arm of UPMC. This brings the total raised in this upsized round to $147 million....Proceeds from the Series B fundraise will be used to advance two investigational TYK2 candidates into the clinic this year."

Financing • Immunology